---

📚 MENOPAUSE - Exam-Oriented Notes

---

1. DEFINITION

• Menopause = Permanent cessation of menstruation at the end of reproductive life due to loss of ovarian follicular activity
• It is the point when last and final menstruation occurs
• Clinical diagnosis confirmed after 12 consecutive months of amenorrhea without any other pathology
• Key rule: Menopause is declared only RETROSPECTIVELY
• Serum FSH elevated around the period of menopause (age 45-55 years)

Menopause Transition

• Period of time when a woman passes from reproductive to non-reproductive stage
• Covers 4-7 years on either side of menopause
• Associated with: elevated serum FSH, variable menstrual cycle length, missed menses

Postmenopause

• The phase of life after menopause

---

2. AGE OF MENOPAUSE

• Age of menopause is genetically predetermined
• NOT related to: age of menarche, last pregnancy, number of pregnancies, lactation, OCP use, socioeconomic condition, race, height, or weight
• Thinner women have early menopause
• Causes of early menopause: cigarette smoking, severe malnutrition
• Range: 45-55 years | Average: 50 years

---

3. CLINICAL IMPORTANCE

• Increased life expectancy → women spend large portion of life in estrogen deficiency stage
• Long-term symptomatic and metabolic complications result from this

---

4. ENDOCRINOLOGY OF MENOPAUSAL TRANSITION

Hypothalamo-Pituitary-Gonadal Axis

• Ovarian follicles become resistant to pituitary gonadotropins
• Effective folliculogenesis is impaired → diminished estradiol production
• Estradiol falls from 50-300 pg/mL (before menopause) to 10-20 pg/mL (after)
• Reduced estradiol → decreased negative feedback on hypothalamo-pituitary axis → FSH increases
• FSH increase is also due to diminished Inhibin (peptide secreted by granulosa cells of ovarian follicle)
• LH increases subsequently
• Disturbed folliculogenesis → anovulation, oligoovulation, premature corpus luteum, corpus luteal insufficiency
• Sustained estrogen levels → can cause endometrial hyperplasia and clinical manifestation of menstrual abnormalities
• Mean cycle length becomes shorter (follicular phase shortens; luteal phase remains constant)
• In late menopausal transition: accelerated rate of follicular depletion
• Ultimately, no more follicles → resistance to gonadotropins → estradiol drops to 20 pg/mL → no endometrial growth → absence of menstruation

---

5. HORMONAL CHANGES AFTER MENOPAUSE

Estrogens

• Predominant estrogen after menopause = Estrone (not estradiol)
• Estrone level: 30-70 pg/mL (higher than estradiol 10-20 pg/mL)
• Main source of estrone = peripheral conversion (aromatization) of androgens from adrenals (mainly) and ovaries
• Aromatization occurs at level of muscle and adipose tissue
• Estrone is biologically less potent (about one-tenth of estradiol)
• 5-10 years after menopause: sharp fall in estrogen and trophic hormones → true menopause

Androgens

• After menopause: stromal cells of ovary continue to produce androgens (androstenedione and testosterone)
• Peripheral androgen levels reduced due to conversion to estrone
• Results in increased estrogen:androgen ratio → increased facial hair growth and voice changes
• Obese patients convert more androgens to estrone → less likely to develop estrogen deficiency symptoms; more vulnerable to endometrial hyperplasia and carcinoma

Progesterone

• Trace amount (probably adrenal)
• Anti-Mullerian Hormone (AMH) levels decreased markedly due to loss of ovarian reserve

Gonadotropins

• Both FSH and LH are increased due to:
  • Absent negative feedback of estradiol and inhibin
  • Enhanced responsiveness of pituitary to GnRH
• FSH rise = 10-20 fold (LH rise = about 3-fold)
• GnRH pulse section increased in frequency and amplitude
• Fall in level of inhibin → increase in FSH from pituitary
• Physiological aging causes both FSH and LH to ultimately decline with decline of estrogens

---

6. ORGAN CHANGES

---

7. BONE METABOLISM

Key Concepts

• Bone formation (osteoblastic) and resorption (osteoclastic) are normally in balance
• After menopause: bone mass loss of 3-5% per year (due to estrogen deficiency)
• Osteoporosis = reduction in bone mass; bone mineral to matrix ratio is normal

Bone Mineral Density (BMD) - T-Scores

• Risk of fracture increased in osteoporosis
• Bone loss primarily in trabecular bone (vertebra, distal radius) and cortical bones
• PTH and IL-1 are involved in osteoporosis
• Estrogen: inhibits osteoclastic activity, inhibits release of IL-1 by monocytes, increases calcium absorption from gut, stimulates calcitonin from thyroid C cells, increases 1,25-dihydroxyvitamin D → increased bone mineralization

Risk Factors for Osteoporosis in Women (TABLE 6.1)

• Family history
• Age > 65 years
• Asian/white race
• Lack of estrogen
• Low body weight/BMI
• Fragility fracture
• Osteopenia, Osteoporosis
• Hypogonadism
• Fall risk factors
• Early menopause (surgical, radiation)
• Dietary: low calcium, low Vit D, high caffeine, smoking, alcohol
• Sedentary habit
• Medications: heparin, corticosteroids, GnRH analogs, anticonvulsants
• Diseases: rheumatoid arthritis, hyperparathyroidism, malabsorption, multiple myeloma, thyroid disorders

Detection of Osteoporosis

• CT and especially DEXA (Dual-energy X-ray absorptiometry) are reliable methods
• Total radiation exposure is higher with CT than DEXA
• FRAX tool (WHO-2001): Calculates 10-year fracture risk probability; considers 11 risk factors; uses femoral neck BMD (gm/cm²)
• Biochemical markers: Urinary calcium/creatinine and hydroxyproline/creatinine ratios

---

8. CARDIOVASCULAR SYSTEM

• Risk of cardiovascular disease high in postmenopausal women due to estrogen deficiency
• Estrogen prevents cardiovascular disease by:
  • Increases HDL2 (high-density lipoprotein)
  • Decreases LDL and total cholesterol
  • Inhibits platelet and macrophage (foam cell) aggregation at vascular intima
  • Stimulates NO (nitric oxide) and prostacyclin from vascular endothelium → dilates blood vessels
  • Prevents atherosclerosis by its antioxidant property
• CV and cerebrovascular effects: oxidation of LDL + foam cell formation → vascular endothelial injury, cell death, smooth muscle proliferation → insulin resistance and central (android) obesity → atherosclerosis, vasoconstriction, thrombus formation

Risk Factors for Cardiovascular Disease (TABLE 6.2)

• Hypertension
• Familial hyperlipidemia
• Smoking habit
• Impaired glucose tolerance

---

9. MENSTRUATION PATTERN PRIOR TO MENOPAUSE

• Abrupt cessation of menstruation (rare)
• Gradual decrease in both amount and duration - may be spotting, delayed, ultimately lead to cessation
• Irregular with or without excessive bleeding - exclude genital malignancy before declaring it the usual premenopausal pattern

---

10. MENOPAUSAL SYMPTOMS

Important Symptoms and Health Concerns

1. Vasomotor symptoms
2. Urogenital atrophy
3. Osteoporosis and fracture
4. Cardiovascular disease
5. Cerebrovascular diseases
6. Psychological changes
7. Skin and hair
8. Sexual dysfunction
9. Dementia and cognitive decline

---

11. SYMPTOMS OF MENOPAUSAL TRANSITION

---

12. DETAILED SYMPTOM ANALYSIS

A. Vasomotor Symptoms (HOT FLASH)

• Most characteristic symptom of menopause
• Characterized by: Sudden feeling of heat followed by profuse sweating
• Other symptoms: palpitation, fatigue, weakness
• Physiologic changes: perspiration and cutaneous vasodilation (under central thermoregulatory control)
• Low estrogen = prerequisite for hot flash
• Hot flash coincides with GnRH pulse secretion with increase in serum LH level
• Duration: 1-10 minutes; sleep may be disturbed (night sweats)
• Thermoregulatory center in hypothalamus is involved in etiology of hot flash
• Gonadotropins (LH) are thought to be involved
• Altered levels of norepinephrine and serotonin also responsible (lower the set point in thermoregulatory center)

B. Genital and Urinary System

• Steroid receptors identified in mucous membrane of urethra, bladder, vagina, and pelvic floor muscles
• Estrogen deficiency → atrophic epithelial changes → dyspareunia and dysuria

Dyspareunia:

• Estradiol deficiency → vaginal dryness or atrophy
• Estrogen replacement reverses atrophic changes
• Can be given orally or vaginally
• 17 β-estradiol tablet or Conjugated Equine Estrogen (CEE) cream is effective
• Risks of endometrial hyperplasia is less with vaginal tablets than cream
• Vaginal lubricants (water soluble) and moisturisers (K-Y jelly) are commonly used

Vaginal Changes:

• Minimal trauma may cause vaginal bleeding
• Also: dyspareunia, vaginal infections, dryness, pruritus, leucorrhea

Urinary Symptoms:

• Urgency, dysuria, and recurrent urinary tract infections (UTI), stress incontinence

C. Sexual Dysfunction

• Estrogen deficiency → decreased sexual desire
• Due to psychological changes (depression anxiety) + atrophic changes of genitourinary system

D. Skin and Hair

• Thinning, loss of elasticity, wrinkling
• Skin collagen content and thickness decrease 1-2% per year
• 'Purse string' wrinkling around mouth; 'crow feet' around eyes are characteristic
• Estrogen receptors present in skin; maximum in facial skin
• Estrogen replacement can prevent skin loss during menopause
• After menopause: loss of pubic and axillary hair; slight balding (low testosterone)

E. Psychological Changes

• Increased frequency: anxiety, headache, insomnia, irritability, dysphasia, depression
• Also: dementia, mood swings, inability to concentrate
• Estrogen increases opioid (neurotransmitter) activity in brain → important for memory

Dementia:

• Estrogen improves cerebral perfusion and cognition
• Not clear whether estrogen therapy prevents vascular dementia and Alzheimer's disease

F. Osteoporosis and Fracture

• Decline in collagenous bone matrix
• Bone mass loss and microarchitectural deterioration primarily in trabecular bone (vertebra, distal radius) and cortical bones
• Bone loss increases to 5% per year during menopause
• Osteoporosis may be:
  • Primary (Type 1): due to estrogen loss, age, deficient nutrition (calcium, Vitamin D), or hereditary
  • Secondary (Type 2): due to endocrine (parathyroid, diabetes) or medication abnormalities
• Fracture may be due to fall of woman (fall risk factors) - reduced muscle mass, cognitive impairment
• Fracture sites: vertebral body, femoral neck, distal forearm (Colles' fracture)
• Morbidity and mortality in elderly women with fracture is HIGH

---

13. DIAGNOSIS OF MENOPAUSE

1. Cessation of menstruation for consecutive 12 months during climacteric
2. Average age: 50 years
3. Appearance of menopausal symptoms - hot flash and night sweats
4. Vaginal cytology: maturation index of at least 10/85/5 (features of low estrogen)
5. Serum estradiol: < 20 pg/mL
6. Serum FSH and LH: > 40 mIU/mL (three values at weekly intervals required)

---

14. MANAGEMENT

Prevention

• Spontaneous menopause: unavoidable
• Artificial menopause (surgery/radiation/chemotherapy): can be prevented or delayed
• Counseling: Every woman with postmenopausal symptoms should be adequately counseled about physiologic events → removes fear, minimizes anxiety, depression, insomnia - Reassurance is essential

Non-Hormonal Treatment

---

15. HIGH-YIELD EXAM POINTS (MNEMONICS & KEY FACTS)

Quick Recall Box

---

Note: These notes cover all major exam-tested topics from the Menopause chapter. Focus especially on the diagnostic criteria, T-score thresholds, hormonal changes, vasomotor symptoms mechanism, bisphosphonate side effects, and the estrone/estradiol distinction - these are the most commonly tested points in clinical exams.

What's inside (4 pages):

• Title banner with chapter reference
• Two-column layouts for Definition, Age, Endocrinology, Symptoms, CVS
• 10+ color-coded tables covering:
  • Hormone levels summary
  • Organ changes
  • T-score BMD classification
  • Osteoporosis risk factors (Table 6.1)
  • CV risk factors (Table 6.2)
  • Menopausal symptoms by category
  • Menstrual patterns
  • Diagnostic criteria
  • Non-hormonal treatments
  • 21-point High-Yield Rapid Recall table at the end
• ★ Red high-yield callouts for the most exam-tested facts
• 📝 Study note reminder at the bottom

---

What's inside (5 pages):